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Abstract
This thesis paper will focus on the most prominent applications in recent research of
immunotherapy in neurodegenerative diseases (specifically Alzheimer’s Disease, Parkinson’s
Disease, and Huntington’s Disease) with a focus on the cellular level on inflammatory pathways
(such as, but not limited to: NFkB, JNK and anti-inflammatory pathways such as NRf2) present
in the human body.

The literary analysis will begin with a basic overview of some of the major homeostatic
pathways present in cellular organelles within the human body (such as the Unfolded Protein
Response/UPR, present in the endoplasmic reticulum of eukaryotes) and how they normally act
within a healthy human body. The paper will then delve deeper into how these cellular processes
are altered, including the root causes of these neurodegenerative diseases commonly researched
today, and what mutations in the normal homeostatic processes mean for the phenotypic display
of these illnesses (how symptoms appear).

The final parts of this literary analysis thesis paper will delve into current research
methodologies being performed in the neurodegenerative disease therapy field and how
immunotherapy is quickly becoming a lead topic of interest amongst researchers and universities
and the benefits (and negatives, if any discovered yet) of using immunotherapy compared to the
alternative (and maybe currently less effective) therapeutic treatments.
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Inflammation within Homeostatic Parameters
One of the first responses to infection is inflammation. This can be in the form of external
inflammation such as puffy eyes, closed sinuses, and a runny nose or internal inflammation such
as the accumulation of lymphocytes in a local lymph node, causing swelling. Neurodegenerative
diseases such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and countless others have
internal inflammation as an integral part of their pathology, which is often associated with
neuronal cell death in the central and peripheral nervous systems.

Inflammation is often a sign of a healthy immune system, contrary to the unregulated
propagation and damage caused by irregular, chronic inflammation present in neurodegenerative
diseases. Regular inflammation is a means by which the human body creates an environment
inhospitable by microbes, such as bacteria or viral particles. The most apparent physical
representation of inflammation in the body is a fever, the human body’s method of increasing the
blood pressure to allow the delivery of immune cells to the site of infection more rapidly and
efficiently.

A fever, however, is a response that is largely the first resort, meaning that it is a natural defense
considered to be part of the innate immune system’s response to foreign invaders/bodies. The
entire immune system is split into two divisions: the innate and the adaptive. These two divisions
are still largely intertwined and immunologists today still don’t really have an explanation for all
the ways that the two parts of our immune systems work together. Fever is only one example of
inflammation that occurs in the body. Inflammatory responses related to fever, when not
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properly regulated by the body’s homeostatic mechanisms, can lead to the neurodegenerative
diseases later explained in this thesis.

The Adaptive and Innate Immune Systems
The innate immune system is crude. It is considered the first line of defense against
infection. Individuals are born with their innate immunity, and it does not change or alter
throughout one’s life. Innate immunity does not learn from microbe to microbe, it only acts on a
set of predetermined instructions for each foreign invader. The innate immune system includes
phagocytes (such as the macrophages that come up and eat away dead cells/tissue after
infection), natural killer cells (cells that are key in the natural defense against tumorous cancer
cells), chemical factors (such as pH and secreted fatty acids), Pathogen Associated Molecular
Patterns (PAMPs) (Toll-like receptors, set of instructions that innately recognize parts of
bacteria/viral particles), natural skin barriers (skin, mucous), neutrophils and mast cells. The
innate immune system does not have a memory like the adaptive immune system, which means it
does not learn from repeated exposures on how to better react to the same antigen/foreign body.
It is non-specific and reacts generally to any foreign entities recognized as non-self by the
immune system.

The adaptive immune system is the more complex of the two and is present only in vertebrates. It
is composed of both B cells and T cells (B and T lymphocytes), both of which are
antigen-specific and only react to very specific foreign substances. When compared to the innate
immune system, which only takes minutes to hours to respond to infection, the adaptive immune
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system requires days to weeks to fully react to infection from foreign bodies. Antigen-specific
cells (B cells and T cells that have recognized an antigen) have a more rigorous response time.
Mature memory B lymphocytes recognize a specific antigen or part of a foreign body and
generate antibodies via clonal expansion. By the creation of these antibodies, which recognize
and tag these antigens for removal innate immune system, the adaptive immune system develops
a memory-like response to these antigens if exposed again to them in the future. It is the
mechanism of creation of antibodies by memory B cells that allows for vaccines to be so
effective. The adaptive immune system can be mediated by the humoral response (B lymphocyte
response), the cell-mediated response (T lymphocyte response), antigen-presenting cells (APCs,
such as B lymphocytes, dendritic cells, and macrophages), natural killer cells (NK cells),
neutrophils, and mast cells. This is why immunologists often say the two divisions of the
immune system are so interlinked; it is common and expected for parts of the innate immune
system to affect and help the adaptive immune system, whether it be in the form of
antigen-presenting cells present in its division such as macrophages or by the early response of
neutrophils that lessen the strength of the infection. Even in cancerous cells or in serious
infections (such as the herpes simplex virus), the natural killer cells of the innate immune system
can act as a backup system for when viruses or tumor cells block the ability of T lymphocytes
from recognizing its antigens and attacking them. Since natural killer cells are not a part of the
adaptive immune system, they are not affected by these types of tricks on the adaptive immune
system.
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In a normal, healthy individual, immune cells such as the ones listed above cannot cross the
blood-brain barrier. The brain heavily relies on microglia, a type of neuroglia cell that supports
neurons in the brain. These microglia act as the ‘immune system’ for the cerebrospinal fluid
(CSF) by sweeping the area of debris and serving as the line of defense for surrounding neuroglia
and neural bodies. It is important to understand how the immune system both in the body and in
the brain work on a regular basis in order to best showcase how neurodegenerative diseases stray
from the norm.

Cytokines
Cytokines are proteins secreted by a broad range of cells within the human body and are
the main factors that cause inflammatory responses, both internally and externally. They are
produced when immune cells such as macrophages, neutrophils, T-cells, or B-cells are triggered
by external factors or proteins that bind to their cell surface. An example of one of these external
factors is Lipopolysaccharide (LPS), which is a major component in the outer membrane of
gram-negative bacteria, which is recognized by Toll-like receptors (PAMPs) in innate cells.

Another example of one of these external factors is the protein Amyloid-beta. When folded
properly and present in the brain at balanced amounts, the Amyloid-beta protein triggers
cytokine production at a rate that doesn’t disrupt the homeostatic balance present in the brain that
is needed for effective communication between immune cells and neurons alike. However, in
AD patients, this protein is misfolded/present in too high amounts, causing aggregation of it in
thick, plaque-like structures between neurons. These plaques effectively block and severely limit
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cell-cell communication. This block of communication eventually leads to major neuronal cell
death, leading to dementia in AD patients. Many developing therapeutics today measure the
release and expression of cytokines between immune cells to determine the strength of an
immune response in both in vitro a nd in vivo models to best predict the way the human immune
system would react to up and coming therapeutic drugs.

These cytokines are produced in the rough endoplasmic reticulum (RER) of the cell. In the RER,
they are folded, later altered post-translationally in the Golgi, and then sent to be released by the
cell. Some of the major cytokines involved in inflammatory immune responses include (but are
not limited to) the interleukins (such as interleukin-6, IL-6 or interleukin-8, IL-8), interferon-γ
(IFN-γ), and tumor necrosis factor-β (TNF-β).

Major Inflammatory and Anti-Inflammatory Cellular Pathways (NF-κB, JNK, NRf2, etc.)
Cell signaling pathways that moderate control over gene transcription and cytokine
production such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), JNK
c-Jun N-terminal kinases (JNK), and nuclear factor erythroid 2–related factor 2 (NRf2) are just a
few of the pathways present in cells that have an important role in inflammation.

As far as NF-κB and JNK, NF-κB activation can have pro-survival, antiapoptotic effects while
JNK signaling has been implicated in the induction of either cell proliferation or apoptosis
(Nikolaou, K. et al., 2013). Short-term activation of JNK pathway induces genes involved in
proliferation control of the cell, specifically in the proliferation of cyclin D1, a protein required
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for progression through the G1 phase of the cell cycle (Nikolaou, K. et al., 2013). Both
cell-signaling pathways are pro-inflammatory in nature and have been shown to work in tandem.
An example of this relationship between the two pathways is their vital role in cancer research in
the determination the cellular factors contributing to inflammation resulting in hepatocellular
carcinoma (HCC), which is the third most common cause of cancer-related mortality worldwide
as well as the most extensively investigated inflammation-based carcinogenic process (Nikolaou,
K. et al., 2013).

While NF-κB has been heavily researched for its role in inflammation leading to cancer, NRf2
has played a major role as an anti-inflammatory cell-signaling pathway in the same field. In a
normal body, reactive oxygen species (ROS) and reactive nitrogen species (RNS) are
accumulated as a result of the many metabolic processes present within cells, such as
proteasomal activity (breakdown of proteins). ROS and RNS contribute to oxidative stress and
when not properly taken care of can lead to chronic inflammation and eventually
cancer/tumorigenesis, neurodegenerative diseases, and more. NRf2 is a cell-signaling pathway
that has been found to combat the accumulation of ROS and RNS in the cell by protecting the
cell by binding to specific antioxidant response elements (AREs) in the promoter of antioxidant
enzymes as well as defense protein genes (Walters, D. M. et al., 2008).

While these cell-signaling pathways are an integral part of the cell’s homeostatic processes, they
can easily become a source of problems instead. An example of this is NRf2 being possibly
utilized by cancer cells or tumors as a protective measure against anti-cancer drugs, creating the
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perfect environment for these tumors to grow and eventually metastasize (Kensler, T. W. et al.,
2010). Although JNK has been seen to work with NF-κB in cancer research surrounding HCC,
chronic JNK activation induces a Bax/Bak-dependent apoptotic pathway, via the mitochondrial
release of cytochrome c (Nikolaou, K. et al., 2 013). This means that although activation of JNK
helps to propagate the activation of NF-κB and pro-survival pathways, continuous and abnormal
activation of JNK is seen to lead to apoptosis of the cell, leading to inflammation and liver
fibrosis.

While it is important to note that inflammation can lead to negative consequences such as
chronic inflammation, cancer, and a host of other ailments, inflammation is normally a regular
part of the cell’s homeostasis. Without inflammation, the cell is not living and not undergoing
metabolic processes. It is when these inflammatory and anti-inflammatory cell-signaling
pathways are not properly working in conjunction with each other and the genes that induce
them that issues arise in the cell, disrupting homeostasis and acting as precursors to disease.

Precursors to Chronic Inflammation
While there are many factors that compose the precursors to developing chronic
inflammation, such as environment or genetic predisposition, there are biological processes on
the cellular level that serve as clear indicators for possible future issues with the homeostatic
balance of inflammation within the body.
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Unfolded Protein Response (UPR)
The Unfolded Protein Response (UPR) is a natural regulatory process within the RER of
cells. The UPR is activated when the lumen of the RER is placed under significant amounts of
stress due to accumulating quantities of misfolded proteins amongst other factors, resulting in the
RER entering a condition of endoplasmic reticulum (ER) stress.

The initial objective of the UPR is to reestablish homeostasis and alleviate ER stress through two
mechanisms: increasing folding capacity via expression of protein-folding chaperones and
downregulation of ER protein client load via inhibiting general protein translation and promoting
the degradation of misfolded proteins (Ozcan, L. et al., 2012). There are many chaperones that
are present within the endoplasmic reticulum. One example of a major protein folding chaperone
is 78-kDa glucose-regulated protein (Grp78), also known as binding immunoglobulin protein
(BiP). The UPR serves as a type of safe-brake for the RER, resorting to the degradation of
proteins that cannot be properly folded after multiple attempts and eventually apoptosis
(programmed cell death) if the UPR is prolonged and the cell cannot settle back into
homeostasis.

There are three major branches of UPR, which are each activated by a dedicated ER-localized
transmembrane molecule: protein kinase RNA-like ER kinase (PERK); inositol-requiring
protein–1 (IRE1); and activating transcription factor–6 (ATF6) (Ozcan, L. et al., 2012). These
pathways are discussed below in the relative depth needed to understand the basic implications
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of chronic stress or inflammation on the RER and its later discussed role in neurodegenerative
diseases.

Out of the three pathways by which the UPR is activated, IRE1 is the most heavily referenced in
literature utilized. IRE1 is usually associated with the BiP/Grp78 chaperone protein in the normal
environment of the RER, and it is when the RER undergoes significant stress that IRE1 is
dissociated from BiP and activated via trans-autophosphorylation. This activation of the IRE1
pathway leads to the mRNA translation of X-box binding protein 1 (XBP1), a transcription
factor which upregulates the genes in the UPR that simultaneously code for higher RER protein
folding capacity and an expanded RER membrane surface for folding. IRE1 has also been found
to show associating with TNF receptor-associated factor-2 (TRAF2), which promotes the JNK
pathway. The JNK pathway, as mentioned before, is a major cell-signaling pathway involved in
apoptosis as well as the inflammatory response in cells and a major contributor to chronic
inflammation present in neurodegenerative diseases.

The PERK pathway of the UPR response is a serine-threonine kinase. Like the IRE1 pathway,
PERK is also activated by trans-autophosphorylation. The activated PERK pathway
phosphorylates eukaryotic translation initiation factor 2 alpha (eLF2α), resulting in a reduced
RER protein load by promoting the translation of activating transcription factor-4 (ATF4) and
inducing the activity of C/EBPα-homologous protein, also known as GADD153 (CHOP). CHOP
expression is similar to JNK activation in that its prolonged activity can trigger apoptosis due to
chronic stress in the RER.
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Out of the three major pathways of the UPR, ATF6, a basic leucine zipper transcription factor, is
the only pathway that directly involves the Golgi complex during its activation. The complex of
ATF6 is moved to the Golgi to be cleaved by Site 1 and Site 2 proteases that break it down
enough to be used as a new, resultant transcription factor. This new transcription factor is
returned to the nucleus of the cell experiencing RER stress to upregulate the genetic expression
of chaperone proteins like BiP/Grp78.

Aggresome/Plaque Formation
When the UPR response is not enough to mitigate the large amounts of misfolded
proteins accumulating in the lumen of the RER, plaques of proteins may form. These plaques
form because while folding, the misfolded protein may assume a three-dimensional structure that
exposes its hydrophobic amino acid side chains to the outside, hydrophilic environment. This
causes misfolded proteins with their hydrophobic side chains exposed as well to aggregate
together, much like oil does in water. Often, there are biological mechanisms in place to prevent
such plaques from forming, such as chaperone proteins (i.e. BiP/Grp78) separating these
misfolded proteins as a function of the UPR. It is when the RER is under immense stress and the
UPR fails that these plaques accumulate at a rate and size that is not easily prevented or
corrected by protein chaperones.

These plaques, termed aggresomes (Johnston, J. et al., 1998), can have a long-lasting negative
effect on the RER by making the stress that activated the UPR pathways in the first place to
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heighten. When proteasome activity (one of the responses of the UPR to degrade misfolded
proteins that cannot be folded properly) was inhibited, these plaques were shown to accumulate
even more (Johnston, J. et al., 1998).

This plaque formation due to heightened misfolded protein accumulation and the failure of the
UPR to mitigate these symptoms occurs in many, if not all, neurodegenerative diseases.

An Overactive Immune System
In the case of many neurodegenerative diseases, plaque formation, when not controlled
by the UPR or proteasomal activity properly, irritates neuroglial populations present within the
brain. This irritation results from plaques hindering cell-cell signaling, causing a response from
microglial populations.

Microglial cells are macrophage derivatives and act as the ‘clean-up crew’ for the brain,
sweeping debris from the surrounding area after a successful defense. Plaque formation triggers
microglial activation, which triggers the release of inflammatory cytokines such as IL-6,
tumor-necrosis factor alpha (TNF-α), etc. In normal amounts, these cytokines simply act as ways
of communication between neuroglial cells. However, when the microglial population
surrounding an area is consistently activated due to the accumulation of aggresomes, the
cytokines can cause chronic inflammation of the surrounding area, inflaming neural bodies and
causing physical damage to both neuroglia and neuron cells alike. It is this mechanism that is
often a part of the pathology of many neurodegenerative diseases, such as AD or PD. It is also
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this area that is of intense focus in the field of immunotherapy when researching the many
factors causing neurodegenerative diseases.

Long-Term Chronic Inflammation (Neuroinflammation) is a Topic of Concern in
Neurodegenerative Diseases
Chronic inflammation contributes to a whole host of health issues, including but not
limited to cancer, autoimmune disorders, and neurological disorders. Even some viruses, such as
herpes simplex-1, are linked with chronic inflammation. Major neurodegenerative diseases are
heavily associated with chronic inflammation, such as AD and other dementias, PD,
Huntington’s Disease (HD), Amyotrophic lateral sclerosis (ALS), Motor Neuron disease, and a
whole host of others.

All these diseases have the disruption in the homeostasis of cell-signaling pathways, genes, and
regular inflammation in common, resulting in the breakdown of neural bodies. While only AD,
PD, and HD are discussed in this literary analysis, many of the immunotherapeutic techniques
mentioned have good future prospects in many, if not all, neurodegenerative diseases.

Alzheimer’s Disease (AD)

AD is a neurodegenerative disease characterized by the formation of amyloid-beta
plaques (aggresomes) and tau tangles surrounding neural bodies within the brain.
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In a healthy brain, neuron cell-cell signaling
progresses normally, allowing for a regulated
environment within the CSF. In patients with AD
or other forms of dementia, this environment is
slowly riddled with neurofibrillary (tau) tangles
and amyloid-beta plaques over time. These
amyloid-beta and tau aggresomes result in a
disruption of the cell-cell signaling of neurons
which eventually leads to the breakdown of the
neural bodies and, in later stages of AD and other forms of dementia, neuron cell death (Figure
1).
Normally, the tau and amyloid-beta proteins are folded correctly within the brain and do not pose
an issue. It is when they are folded improperly, with their hydrophobic side chains exposed so
that they cluster together to form rafts within the CSF, that an issue such as dementia can
eventually arise. This clustering of proteins causes chronic inflammation within the brain,
resulting in a hyperactive microglia population and the release of more inflammatory cytokines
by these neuroglia, such as IL-6. The overcompensation of cytokine release in an effort to
communicate with other microglia for the need to clean the ‘debris’ (the plaques and tangles)
results in a chronically irritated immune system. This only propagates the issue of chronic
inflammation further and leads to the worsening of dementia/AD symptoms, including but not
limited to memory loss.
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Alzheimer’s Disease: Immunotherapeutic Advances
Many of the immunotherapeutic approaches to AD include passive immunization, active
immunization, the use of microglia to sweep debris and target misfolded amyloid-beta plaques
and tau tangles, as well as the administration of neuroprotective molecules (derived usually from
plant sources).
Passive immunization, as explained before, is the placement of readily-made antibodies towards
a specific antigen placed into the host/individual to be immunogenized. Active immunization
involves the body’s cells direct reaction and creation of antibodies within the body to antigens
presented by APCs such as B lymphocytes, which elicit a reaction from T lymphocytes (either
CD4 T-helper cells or CD8 cytotoxic T-cells). In the first study of anti-amyloid beta
immunization ever, transgenic mice models of AD were immunized against amyloid-beta via a
vaccine that supported both passive and active immunization, meaning that antibodies were
readily in the vaccine as well as antigens of amyloid-beta to allow for the mice’s immune system
to create their own antibodies against the molecule (Schenk et al.,1999). The use of both active
and passive immunization is a prevalent area of research when it comes to immunotherapy of
AD despite frequently running into new health concerns that appear during later stages of in vivo
human studies. An example of this issue is a phase II clinical trial utilizing active immunization
against amyloid-beta that was discontinued because of the development of severe
meningoencephalitis (meningitis of the brain) in 6% of the patients (Hung et al., 2 017). In recent
clinical trials, anti-amyloid beta monoclonal antibodies are being used (such as solanezumab)
against amyloid-beta plaque aggresomes in AD patients and seen to have some improvement in
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the cognition in those with mild AD symptoms (Rygiel, 2016). This clinical trial with
solanezumab unfortunately did not meet its primary endpoint in phase III and is now being tested
in a prevention study with older subjects who show amyloid-beta deposits but no AD symptoms
(Hung et al., 2 017). Other drugs, such as crenezumab, a monoclonal antibody with a higher
affinity for oligomeric/fibrillar amyloid-beta plaques than the usually asymptomatic monomeric
amyloid-beta, are in Phase III clinical trial studies and show promise for treatment of
amyloid-beta aggresomes via passive immunization (Hung et al., 2017). One drug currently still
active in phase III clinical trials, aducanumab, has demonstrated an ability to significantly reduce
the number of amyloid-beta aggresomes in AD patients (Sevigny, J. et al., 2016). Targeting
neurofibrillary tangles (NFTs; hyperphosphorylated tau aggresomes) is also a route of interest.
However, most of the current clinical trials on clearing tau tangles involve active immunization,
an example being the AADvac1 drug (currently in phase 2 of clinical trials), which aims to treat
patients with mild Alzheimer’s disease (Panza, F. et al., 2016).
Anti-tau passive immunization could be a potential path of AD immunotherapy in the future, but
few studies have been done on anti-tau immunization that is not active immunization. That is not
to say that all AD immunotherapy involving anti-tau treatment involve only active
immunization. Passive immunization of tau tangles by the treatment of triple-transgenic AD
mice with 43D and 77E9 antibodies against multiple forms of tau and amyloid-beta resulted in a
reduced pathology of tau, hyperphosphorylated tau tangles, amyloid precursor protein (APP),
and amyloid-beta aggresomes (Dai, C. et al., 2017).
Other methods of passive immunization include plaque disaggregation, Fc receptor (FcR)
mediated phagocytosis, and the Peripheral Sink Mechanism (Figure 2). All three of these
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methods involve the injection of antibodies to the protein being targeted, whether it be
hyperphosphorylated tau or amyloid-beta.

Plaque disaggregation involves
Fab-fragment binding of
anti-amyloid-beta to amyloid-beta
protein and subsequent proteasomal
degradation of these marked antigens.
Inhibition of the formation of
fibrillar, cytotoxic amyloid-beta
aggresomes usually involves targeting
a certain terminus of misfolded amyloid-beta species with monoclonal antibodies to discourage
plaque aggregation. This method was used in the prevention of the formation of amyloid-beta
aggresomes with antibodies that targeted the C-terminal of two forms of amyloid-beta
(Montañés, M. et al., 2013). With this method, it’s important for researchers in the future to
carefully consider exactly which terminus is selected for antibody formation. One study showed
that an anti-amyloid antibody that targeted the N-terminus of amyloid-beta species encouraged
the amyloid-beta to form into neurotoxic oligomer aggresomes rather than having the opposite,
intended effect of alleviating such plaque formation (Liu, Y. et al., 2015). FcR-mediated
Phagocytosis involves the recruitment of microglial cells to amyloid-beta aggresomes plaques
and degradation via activation of the FcR microglia receptor sites by IgGs, a subtype of
antibody. The peripheral sink mechanism involves flushing/off-loading of CSF amyloid-beta
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populations through the blood-brain barrier, where antibodies on the other side can mark the
proteins for immune response. While the peripheral sink hypothesis is, in theory, a method that
could allow for the treatment of AD symptoms without having to design medicine that is able to
cross the blood-brain barrier, it has shown mixed results in practice. Some treatments utilizing
the peripheral sink hypothesis work, and some do not. For instance, treatment of Tg2576 mice
with enoxaparin, an anticoagulant medication, resulted in amyloid-beta aggresome pathology
worsening, which was indicated by a significant increase in the
amyloid-beta-42/amyloid-beta-40 ratios in the brain as well as encouraged aggresomes of both
amyloid-beta species in vitro (Cui, H. et al., 2016). Other studies show that the while the
peripheral sink hypothesis can sometimes result in a decrease in amyloid-beta levels in the brain
due to an inhibition of the gene β-secretase (BACE)1 via inhibitors in the peripheral immune
system, the reduction is simply not enough to indicate that BACE1 inhibition is the rate-limiting
enzyme for amyloid-beta degradation in the CSF or that the peripheral sink hypothesis is
anything other that just that: a hypothesis (Georgievska, B. et al., 2014). A similar study was
performed analyzing the effect that neprilysin, an amyloid-beta degrading enzyme, had on
amyloid-beta populations within the brain compared to the CSF (Henderson, S. J. et al., 2013).
This study also found that while the molecule studied was highly effective at decreasing the
prevalence of amyloid-beta aggresomes in the periphery, it did not alter CSF amyloid-beta
levels, therefore also disproving the peripheral sink hypothesis. While there is significant
evidence that the peripheral sink hypothesis is currently nothing more than an ideal concept,
there is still research being done on its possibility as a new immunotherapeutic strategy in AD in
the future (Menendez-Gonzalez, M. et al., 2018).
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Another area of interest in terms of treatment of AD includes the use of neuroprotective
molecules to combat neuroinflammation and decrease plaque aggresomes cytotoxicity in AD
brain models. Asiatic acid (AA), a triterpene of a pennywort plant called Centella (Centella
asiatica) has been shown to mitigate oxidative stress in the CSF of an in vivo AlCl3-induced
AD-model mice (Thenmozhi, A. J., 2018).

Parkinson’s Disease (PD)
Parkinson’s Disease (PD) is characterized by the loss of dopaminergic neurons within the
Substantia nigra Pars Compacta (SnPC), a cluster of brain tissue that runs from the top of the
pons in the spinal cord through the midbrain (Figure 3). The death of these dopaminergic
neurons is caused by an increased presence of
Lewy bodies-- aggresomes of a protein
exclusive to neurons called
α-Synuclein—within the CSF, leading to reduce
dopamine production and a subsequent decrease
in cell-to-cell communication between neurons
within the SnPc (Kalia et al., 2015).
The natural response of astrocytes and
microglia present in the brain is to try and clean
out these aggresomes plaques of α-Synuclein to restore homeostasis within the CSF so that
communication between the neurons through neurotransmitters is restored to normal. However,
as is the case with most neurodegenerative diseases, this neuroinflammatory response can
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sometimes exceed homeostatic control and become unregulated—overactive microglia and
astrocytes can contribute to the accumulation of cytokine proteins within the brain’s
environment, further propagating the chronic inflammation resulting from the presence of Lewy
bodies around dopaminergic neurons. This is due to the microglia’s ROS pathway being
overstimulated due to a high presence of misfolded proteins within the CSF, resulting in a higher
presence of oxidative species, the activation of pro-inflammatory pathways like NF-κB and more
cytokine production and neuroinflammation.
Parkinson’s Disease: Immunotherapeutic Advances
The treatment of neuroinflammation is a major area of immunotherapy for Parkinson’s
disease. Nonsteroidal anti-inflammatory medicine (NSAIDs) has shown to have a statistically
significant relation to a reduced risk of PD—a risk reduction of approximately 17%— via
meta-analysis of published research studies (Noyce et al., 2012). This indicates a relation
between decreased inflammation or the treatment of possible inflammation that the precursors or
risk factors of PD could cause within the SnPC by anti-inflammatory drugs could be a possible
preventative measure (or treatment) for chronic inflammation resulting from PD-like symptoms.
Neuroinflammation is related to an increase in oxidative stress by the overactivation of the ROS
cellular pathway in microglia. Mitochondrial dysfunction, which is also a symptom of PD, can
result in an increase in oxidative stress due to the disruption of homeostatic parameters of
calcium channels within the neuron cells. Urate (a salt of uric acid) is known to have antioxidant
properties and has been shown to reduce oxidative stress from neuroinflammation and
mitochondrial dysfunction in cellular models as well as reduce the oxidation of dopamine in the
SnPC neurons within actual PD patients (Cipriani et al., 2010). Urate was found to act as both a
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biomarker (predictor of disease-like symptoms and development) for progression of PD but also
as a neuroprotectant molecule for SnPC neurons within PD patients (Chen et al., 2012).
Plant-based derivatives and alternatives as neuroprotective biomolecules is also a prevalent area
of research. Mulberrin, a key component of a Chinese herb Ramulus mori, was used in both in
vivo via the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Sprague
Dawley rats and in vitro via the administration of LPS as a positive control to BV-2 cells, an
immortalized murine microglial cell line as a neuroprotector and was found to have suppressed
both neuroinflammation and oxidative stress in both experiments (Cao et al., 2019). Thymol, a
phenol derivative of the spice thyme, was administered to a PD model (induced by rotenone,
causing rotenone (ROT) induced neurodegeneration in mice) of Male Wister rats and found to
have significantly reduced dopaminergic neuronal death, neuroinflammation, and oxidative
stress in the rats via thymol’s action as an antioxidant against ROT-induced neurotoxicity,
amongst other mechanisms (Javed et al., 2019). A similar in vivo experiment involved treating
aged, ROT-induced PD model rats with kolaviron (a derivative of Garcinia kola seeds) indicated
that treatment with kolaviron resulted in an improved mobility and coordination of the affected
rats, exhibiting the derivative’s neuroprotective, anti-inflammatory, and antioxidant properties
(Farombi et al., 2 019).
Another area of immunotherapy research in PD involves studying the effects of the mutation of
the leucine-rich repeat kinase 2 (LRRK2) gene, which is heavily involved in PD pathology. The
G2019s LRRK2 mutation is the most common one, increasing kinase activity and resulting in
neuroinflammation from the cytokines (inflammatory ones such as TNFα) produced from this
kinase activation (Connor-Robson et al., 2019). In a study with in vitro BV-2 microglia,
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microglia cells were activated by LPS (as a positive control) and activated LRRK2 kinase,
resulting in a significant increase in TNFα release and subsequent neuronal cell death (Ho et al.,
2019). In the same study but with in vivo GS mice models, TNFα levels in brains of GS mice
was significantly higher than mice without the GS mutation; only when the LRRK2 kinase gene
was inhibited was this increase in pro-inflammatory cytokines resolved. In another in vivo study
involving LRRK2 G2019S transgenic mice, α-Synuclein aggregation was found to have
increased, resulting in the death of dopaminergic neurons in the SnPC of the mice and increased
neuroinflammation (and related loss of coordination) (Bieri et al., 2019). In the same study,
researchers created a PD-like model of α-Synuclein aggregation with iPS (Induced Pluripotent
Stem cells) derived neurons (iNs) that showcased an increase in α-Synuclein protein aggregation
with the presence of the G2019S mutation and a decrease in α-Synuclein aggregation when the
LRRK2 gene was inhibited. G2019S LRRK2 has also been found to activate the
MKK4-JNK-c-Jun pro-inflammatory cellular pathway in the SnPC, resulting in loss of SnPC
dopaminergic neurons in a PD model of 12-16-month-old (aged) GS-LRRK2 transgenic mice
(Chen et al., 2012).
Targeting α-Synuclein protein aggregation itself is also a prominent area of interest regarding
immunotherapy of PD. Measuring the UPR that is triggered in the ER due to an increased
prevalence of misfolded α-Synuclein and using neuroprotective molecules to target folding
chaperones such as Grp78 and BiP can contribute to a decrease in neuroinflammation resulting
from a prolonged, chronic activation of the UPR (Enogieru et al., 2 019). Another approach that
targets α-Synuclein is the use of α-Synuclein antibodies. α-Synuclein monoclonal antibodies
(mAbs) were shown to reduce α-Synuclein formation of Lewy bodies in culture, resulting in a
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decrease of neuronal cell death and inhibiting the spread of misfolded α-Synuclein pathology
(Tran et al., 2014). One review highlighted the importance of antibodies against misfolded
α-Synuclein so that microglial cells in the CSF can degrade them and prevent these misfolded
proteins from transferring extracellularly and progressing PD pathology (George, S. et al., 2 015).
Huntington’s Disease
Huntington’s Disease (HD) is a neurodegenerative disease characterized by chorea
(uncontrolled and sporadic movement and loss of motor control), dystonia, and parkinsonism
(Gövert, F. et al., 2013). HD results in an abnormally high occurrence of trinucleotide repeats
(TNTs) in the genome of the patient, resulting in significant differences in genetic expression in
the form of changes in phenotypic display (motor function). These TNTs occur in CAG repeats,
nucleotide base-pairs in DNA consisting of
cytosine, adenine, and guanine that code for
glutamine (Kim, S. D. et al., 2014) (Figure
4). Huntington’s disease is passed on from
generation to generation via autosomal
dominant inheritance, meaning that the
disease mutation does not skip generations
and is present in all homozygous dominant
and heterozygous offspring.
Huntington’s Disease: Immunotherapeutic Advances
Much of the research done relating to immunotherapy for HD is done in conjunction with
other major neurodegenerative diseases such as AD, PD, and ALS. Immunotherapy focused on
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HD alone is a relatively new field, with many of the studies done so far being rather limited
compared to that of other neurodegenerative diseases. The main areas of immunotherapy of HD
include research done with neuroprotective molecules on neuronal cell bodies within the brain as
well as passive immunization via Fab-fragment induced phagocytosis. Active immunization of
mHTT research in HD is severely limited in quantity as well as results; the research done in this
branch of immunization is rather superficial currently but has good prospects for the future.
As mentioned, studies done on neuroprotective molecules and their effect on mHTT are the more
prevalent variety of immunotherapy for HD. Eicosapentaenoic acid (Ethyl-EPA), an omega-fatty
acid, was a phase III clinical trial held in 2005 that only produced improved chorea score
(amongst other scores) in HD patients with a CAG lower than 45 TNTs (Denis, H. et al., 2018).
Despite this clinical trial not going as planned necessarily, EPA has been shown to inactivate
both JNK and NF-κB pro-neuroinflammatory pathways as well as mark a reduction in the
secretion of TNFα messenger ribonucleic acid (mRNA) in culture with murine BV-2 microglia
(Moon, D. et al., 2 007). NF-κB inactivation has also occurred in human monocyte cells when
treated with EPA (Zhao, Y. et al., 2004). Inactivation of these pro-inflammatory cellular
pathways is indicative of neuroprotection and EPA’s potential as a future treatment for
neuroinflammation resulting from aggresome plaque formation of mHTT accumulation within
the CSF. Another clinical trial (phase 2) testing the effect of a neuroprotective molecule on
neurodegeneration was completed in 2015 was with Epigallocatechin gallate (EGCG), a green
tea polyphenol, but unfortunately never had results released for it (Denis, H. et al., 2 018).
EGCG, like EPA, has also been shown to inactivate NF-κB activity; this was observed in a study
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involving the monitoring of microglial activation in an ALS transgenic mice model (Xu, Z. et al.,
2006).
Passive immunization in HD involves targeting mHTT via mechanisms like Fab-fragment (from
IgG monoclonal antibodies) induced phagocytosis, like the mechanism presented in the AD
portion of this review. These intrabodies target a specific protein in a cell by antibody-antigen
recognition. Targeting the N-terminus of HTT with monoclonal antibodies resulted in a decrease
of mHTT plaque aggresomes and reduce cytotoxicity in vitro (Lecerf, J. et al., 2001).
Active immunization in HD, as mentioned previously, is an area of research that still appears
rather shallow and undeveloped in comparison to studies done on active immunization as an
immunotherapy method in other, related neurodegenerative diseases. Very few studies have been
cited in literature and those that have are usually more speculative in nature. A recent 2015 study
by Ramsingh, A. I. et al. used a R6/1, zQ175 mice model to test the safety of active
immunization through vaccines of peptide, protein and DNA plasmids. This study, however, did
not produce any results regarding the actual pathology of HD in the mice model—it simply
discussed the immune responses that these vaccines (in combination with certain adjuvants such
as alum) caused in the transgenic mice.

Future Outlooks: Ethics and Safety with Immunotherapy
Despite immunotherapy having a lot of potential in terms of a new methodology of
treatment for neurodegenerative diseases, it is still a relatively new field of research—in some
diseases, such as AD, only having study data from over the past two decades.

DocuSign Envelope ID: DCA44B95-F643-44C8-83E3-DC05B36AE5AE

This brings up a question of safety and health concerns regarding immunotherapy—a lot of the
concepts surrounding many of immunotherapy and these neurodegenerative diseases is based on
the speculation of relation-based science; ‘this’ molecule has neuroprotective properties against
ROS’ oxidative species in vitro, so it could lead to a decrease in pathology in ‘this disease’ in
vivo. This is a realistic route to take, given that is the foundation for most medicine-related
research. As long as the evidence of neuroprotection from the molecule in a disease-like model
(whether it be cellular or in mice) is significant, then the next step would logically be to try it
with more complex organisms to further gather data on its potential as a neuroprotective
molecule or effective method of decreasing pathology. Unfortunately, this thought process when
applied to immunotherapy often does not result in the preferred, optimal results—results being
that a researched neuroprotective molecule does not result in a clinically significant decrease in
pathology of a neurodegenerative disease; an example of this is was the drug Avagacestat, a
γ-secretase inhibitor, in its phase II clinical trials for the treatment of AD, which was
discontinued in 2012 due to trends of the disease pathology worsening in terms of cognition at
higher doses (Coric, V. et al., 2 012).
This same trial (Coric, V. et al., 2012) was also found to pose health risks to the patients, some
even developing nonmelanoma skin cancer. In another clinical trial for Alzheimer’s disease, the
study was terminated in phase II due to 6% of the patients developing severe
meningoencephalitis, which is counterintuitive to the whole goal of immunotherapy targeting
neuroinflammation (Holmes, C. et al., 2008). This showcases the critical issue of
immunotherapy not only having the opposite of the intended effect in clinical studies, but also
possibly leading to other adverse effects to patients’ health.
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Another topic of concern is something that all clinical trial studies are subjugated—the reaction
of the treatment being tested with already FDA-approved, prescribed or over-the-counter (OTC)
medications. While not much in terms of data showing that these neuroprotective derivatives
react adversely with certain medications, this is a topic of concern that will only increase to
garner more focus as new immunotherapies enter clinical studies. Nearly 50% of the approved
drugs from the last three decades are somehow derived from natural products (whether it be
plant-based or some other source) in cancer treatment alone (Veeresham, C., 2012). Many of the
major neurodegenerative diseases are heavily associated with the elderly; it is both of a logical
and ethical concern to consider the effects that future immunotherapeutic drugs might have on
the patient(s) when mixed with drugs commonly taken by the older population, including but not
limited to blood pressure medicine, Beta-blockers, Calcium channel blockers, and so on.

Conclusion
Immunotherapy is an up-and-coming field of research in neurodegenerative diseases that
has a lot of promise—in terms of conceptual science and theories, the precursors of a valid and
clinically significant alternative form of treatment are there amongst the many pathways
currently being explored by researchers. Despite the setbacks that the field have experienced so
far in terms of non-optimal results from clinical studies, immunotherapy is a relatively new field
of interest. Many clinical trials regarding immunotherapy, whether it be the testing of
neuroprotective molecules against disease pathology, or active/passive immunization against the
proteins that propagate these diseases, have occurred only within the last decade. The field has a
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lot of area to grow and explore, and many of the techniques being studied in immunotherapy are
applicable to multiple neurodegenerative diseases, especially those regarding neuroinflammation.
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